Swiss army knife with various antibodies attached

Multispecific antibodies in oncology

Learn more about this and other topics in our July issue

  • Maria-Elisabeth Goebeler
  • Gernot Stuhler
  • Ralf Bargou
Review Article


  • charts overlaid with maps

    In this Collection, you can find the latest articles published in Nature Reviews Clinical Oncology that discuss trends in cancer incidence and mortality.

  • viral particles floating

    Read all the COVID-19-related contents published in our journal, which will be freely available during the pandemic.


    • BCMA-directed chimeric antigen receptor T cell therapies and bispecific T cell engagers are moving to earlier lines of therapy in multiple myeloma. In addition, combination therapy with the BCMA-targeting antibody–drug conjugate belantamab mafodotin at first or subsequent relapse has the potential to improve survival of patients with this disease. This increasing number of therapeutic options makes treatment selection and sequencing increasingly complex.

      • Niels W. C. J. van de Donk
      • Sonja Zweegman
      News & Views
    • Chromosomal instability (CIN) is a dynamic phenotype characterized by changes in chromosome number and structure and is a hallmark of clinically aggressive malignancies. Nonetheless, the ability of cancer cells to tolerate CIN creates several potential therapeutic vulnerabilities. In this Review, the authors describe the development of CIN and how this phenotype promotes carcinogenesis and tumour progression as well as describing the various attempts to develop targeted therapies based on the specific vulnerabilities of these tumours.

      • Duaa H. Al-Rawi
      • Emanuele Lettera
      • Samuel F. Bakhoum
      Review Article
    • The NETTER-2 trial provides the first phase III evidence that 177Lu-dotatate is active as first-line therapy in patients with gastroenteropancreatic neuroendocrine tumours with a Ki-67 proliferative index of 10–55%. This approach is an important addition to the first-line therapeutic armamentarium, although treatment selection based on patient-specific and tumour-specific characteristics remains appropriate.

      • Jonathan Strosberg
      • Mauro Cives
      News & Views
    • Traditionally, patients with small-cell lung cancer (SCLC), a malignancy with a dismal prognosis, have had limited treatment options. Over the past few years, advances in the molecular characterization of SCLC have revealed novel therapeutic targets. The authors of this Review summarize these findings and discuss emerging opportunities and challenges for their translation into new treatment approaches.

      • Triparna Sen
      • Nobuyuki Takahashi
      • Abdul Rafeh Naqash
      Review Article
    • Novel immunotherapeutic strategies based on targeting specific tumour-associated antigens with antibody–drug conjugates (ADCs), chimeric antigen receptor (CAR) T cells and bispecific T cell engagers (BTEs) are revolutionizing the treatment of multiple myeloma. In this Review, the authors describe the clinical experience to date with ADCs, CAR T cells and BTEs targeting B cell maturation antigen, G protein-coupled receptor family C group 5 member D and Fc receptor-like protein 5. In addition, they discuss the mechanisms of resistance to such therapies, and potential strategies by which resistance could be overcome to improve patient outcomes.

      • Paola Neri
      • Noémie Leblay
      • Kenneth C. Anderson
      Review Article

Nature Careers

Science jobs